https://sofinnovapartners.com/news/abx464-inhibits-replication-sars-cov-2-covid-19-reconstituted-human
Abivax's ABX464 inhibits SARS-CoV-2 replication in vitro — Sofinnova Partners
May 14, 2020 - Abivax's ABX464 inhibits SARS-CoV-2 in a lung epithelium model with triple action: antiviral, anti-inflammatory and tissue repair. Phase 2b/3 trial approved.
sars covin vitroabivaxinhibitsreplication
https://sofinnovapartners.com/news/disco-pharmaceuticals-launches-surfaceome-company-eur-20-million-seed
DISCO Pharmaceuticals launches with €20M seed financing — Sofinnova Partners
Jan 16, 2024 - DISCO Pharmaceuticals raises €20M in seed financing to map cancer cell surfaceomes and identify novel oncology drug targets, led by Sofinnova Partners.
discopharmaceuticalslaunchesseedfinancing
https://sofinnovapartners.com/news/asceneuron-secures-usd100-million-series-c-financing-advance
Asceneuron raises $100M Series C for Alzheimer's drug — Sofinnova Partners
Jul 16, 2024 - Asceneuron closes a $100M Series C led by Novo Holdings to advance ASN51, an oral OGA inhibitor targeting tau, into Phase 2 for Alzheimer's disease.
series craisesalzheimerdrugsofinnova
https://www.sofinnova.com/team/smita-chowdhri/
Smita Chowdhri | Sofinnova
Jun 8, 2026 - Smita joined Sofinnova BioEquities as a Controller in 2026. She focuses on accounting and finance for the public equity team. Prior to Sofinnova, Smita was the...
smitasofinnova
https://sofinnovapartners.com/news/cellcentric-oversubscribed-usd220-million-series-d-financing
CellCentric raises $220M Series D for inobrodib trials — Sofinnova Partners
May 6, 2026 - CellCentric closes a $220M Series D, with Sofinnova among investors, to advance pivotal trials of inobrodib in relapsed or refractory multiple myeloma.
series draisestrialssofinnovapartners
https://www.venturecapitaljournal.com/elan-rd-chief-joins-sofinnova-ventures-2/
Elan R&D Chief Joins Sofinnova Ventures
Sep 19, 2008 - Lars Ekman has joined Sofinnova Ventures as a San Diego-based executive-in-residence. He previously was with Elan Corp., where he served as executive VP and...
r delanchiefjoinssofinnova
https://sofinnovapartners.com/news/enginzyme-tetra-pak-join-forces-advance-sustainable-food-beverage
EnginZyme and Tetra Pak partner on sustainable food production — Sofinnova Partners
Jun 2, 2022 - EnginZyme and Tetra Pak partner on enzyme-based food production, applying cell-free biomanufacturing to convert food waste into ingredients.
sustainable food productiontetra pakpartnersofinnova
https://sofinnovapartners.com/news/lupin-and-tenpoint-therapeutics-announce-strategic-partnership-to-commercialize-yuvezzi-in-the-european-union-the-united-kingdom-switzerland-norway-and-iceland
Lupin and Tenpoint Therapeutics announce strategic partnership to commercialize YUVEZZI — Sofinnova...
Aug 20, 2026 - Lupin Limited has secured exclusive rights to sell YUVEZZI™, a new eye treatment for age-related vision problems, across Europe and the UK
strategic partnershiplupintherapeuticsannouncecommercialize
https://www.marketdash.com/hedge-funds/SOFINNOVA%20INVESTMENTS%2C%20INC.
Sofinnova Investments Hedge Fund Holdings & 13F Portfolio - MarketDash
Track Sofinnova Investments's latest 13F portfolio holdings, largest trades, and investment activity. AUM, top positions, and quarterly changes.
sofinnova investmentshedge fundholdingsportfolio
https://sofinnovapartners.com/features/healthcare-in-the-post-covid-era-where-is-cell-and-gene-therapy-going
Healthcare in the post-COVID era, where is Cell and Gene Therapy going? — Sofinnova Partners
Feb 28, 2025 - Abstract The post-COVID era has posed significant challenges to the pharmaceutical industry due to factors like raw material shortages from disrupted global…
in the postgene therapyhealthcarecovidcell
https://sofinnovapartners.com/news/corwave-second-closing-series-c-funding-eur61m
CorWave closes €61M Series C to fund industrial deployment — Sofinnova Partners
Jun 20, 2023 - CorWave raises €61M in its Series C second closing, led by Bpifrance's SPI fund, to finance its first industrial deployment and entry into clinical trials.
series cclosesfundindustrialdeployment
https://sofinnovapartners.com/
Sofinnova Partners — Life Sciences Venture Capital — Sofinnova Partners
Sofinnova Partners invests in life sciences innovation worldwide, from biopharma and medtech to digital medicine and industrial biotech.
life sciencesventure capitalsofinnovapartners
https://sofinnovapartners.com/news/pixium-vision-fda-breakthrough-device-designation-prima-system-dry-amd
Pixium Vision wins FDA Breakthrough Device Designation — Sofinnova Partners
Mar 31, 2023 - Pixium Vision gets FDA Breakthrough Device Designation for its Prima System in dry AMD, expediting development and US regulatory review.
fda breakthrough devicepixium visionwinsdesignationsofinnova
https://www.sofinnova.com/categories-team/public-administrative/
Public Archives | Sofinnova
publicarchivessofinnova
https://forbion.com/news-insights/news/forbion-capital-partners-and-sofinnova-participate-in-the-7-million-series-a-financing-of-hookipa-biotech/
Forbion and Sofinnova participate in €7M Series A Financing | Forbion
Forbion Capital Partners and Sofinnova participate in the €7 million Series A Financing of Hookipa Biotech
series a financingsofinnovaparticipate
https://sofinnovapartners.com/legal-terms
Legal Terms — Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and...
legal termssofinnovapartners